Dimensional Fund Advisors LP Apellis Pharmaceuticals, Inc. Transaction History

Dimensional Fund Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$38.07 - $59.71 $1.31 Million - $2.06 Million	-34,448 Reduced 50.55%	33,696 $1.29 Million
Q1 2024 May 10, 2024	BUY	$55.39 - $72.47 $1.8 Million - $2.36 Million	32,577 Added 91.59%	68,144 $4.01 Million
Q4 2023 Feb 07, 2024	BUY	$37.14 - $64.82 $352,830 - $615,789	9,500 Added 36.44%	35,567 $2.13 Million
Q3 2023 Nov 09, 2023	SELL	$23.65 - $89.22 $2.5 Million - $9.43 Million	-105,720 Reduced 80.22%	26,067 $991,000
Q2 2023 Aug 09, 2023	BUY	$76.68 - $93.31 $2.9 Million - $3.53 Million	37,801 Added 40.22%	131,787 $12 Million
Q1 2023 May 12, 2023	BUY	$46.59 - $66.96 $2.47 Million - $3.55 Million	52,979 Added 129.2%	93,986 $6.2 Million
Q4 2022 Feb 09, 2023	SELL	$43.24 - $61.04 $1.8 Million - $2.54 Million	-41,587 Reduced 50.35%	41,007 $2.12 Million
Q3 2022 Nov 10, 2022	BUY	$44.76 - $69.66 $3.7 Million - $5.75 Million	82,594 New	82,594 $5.64 Million
Q1 2022 May 13, 2022	SELL	$35.46 - $54.12 $348,500 - $531,891	-9,828 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$30.74 - $49.16 $17,644 - $28,217	-574 Reduced 5.52%	9,828 $465,000
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $326,622 - $726,475	10,402 New	10,402 $343,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.